127 related articles for article (PubMed ID: 23948750)
1. Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer.
Youssef G; Gillett C; Agbaje O; Crompton T; Montano X
Mod Pathol; 2014 Mar; 27(3):361-74. PubMed ID: 23948750
[TBL] [Abstract][Full Text] [Related]
2. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
[TBL] [Abstract][Full Text] [Related]
3. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Montano X
Oncogene; 2009 Oct; 28(43):3787-800. PubMed ID: 19749791
[TBL] [Abstract][Full Text] [Related]
4. A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients.
Currie D; Wong N; Zane I; Rix T; Vardakastanis M; Claxton A; Ong KKV; Macmorland W; Poivet A; Brooks A; Niola P; Huntley D; Montano X
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398114
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
6. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
8. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y
Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905
[No Abstract] [Full Text] [Related]
9. Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Liu L; Zhang S; Liu X; Liu J
Mol Med Rep; 2019 Apr; 19(4):3273-3282. PubMed ID: 30816454
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
11. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
12. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
13. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
15. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Lin CH; Chen IC; Huang CS; Hu FC; Kuo WH; Kuo KT; Wang CC; Wu PF; Chang DY; Wang MY; Chang CH; Chen WW; Lu YS; Cheng AL
Sci Rep; 2015 Dec; 5():17879. PubMed ID: 26671300
[TBL] [Abstract][Full Text] [Related]
16. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
[TBL] [Abstract][Full Text] [Related]
17. PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Sooman L; Ekman S; Tsakonas G; Jaiswal A; Navani S; Edqvist PH; Pontén F; Bergström S; Johansson M; Wu X; Blomquist E; Bergqvist M; Gullbo J; Lennartsson J
Tumour Biol; 2014 May; 35(5):4479-88. PubMed ID: 24510345
[TBL] [Abstract][Full Text] [Related]
18. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
19. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
Asano T; Sato S; Yoshimoto N; Endo Y; Hato Y; Dong Y; Takahashi S; Fujii Y; Toyama T
Jpn J Clin Oncol; 2014 Oct; 44(10):889-97. PubMed ID: 25163465
[TBL] [Abstract][Full Text] [Related]
20. Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.
Bergsneider B; Bailey E; Ahmed Y; Gogineni N; Huntley D; Montano X
Biochem Biophys Rep; 2021 Sep; 27():101081. PubMed ID: 34307909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
